NASDAQ:ELGX - Endologix Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0.30 (1.20%)
Get New Endologix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ELGX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ELGX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
This price target is based on 0 analysts offering 12 month price targets for Endologix in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Endologix. This rating has held steady since April 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/24/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/18/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2020BTIG ResearchDowngradeBuy ➝ NeutralHigh
i
Rating by Marie Thibault at BTIG Research
3/23/2020StephensLower Price TargetEqual Weight$3.00 ➝ $2.00Low
i
2/25/2020BTIG ResearchReiterated RatingBuy$6.00High
i
2/20/2020Piper SandlerLower Price Target$1.00Low
i
2/20/2020StephensLower Price TargetEqual Weight$7.00 ➝ $3.00High
i
8/9/2019Royal Bank of CanadaSet Price TargetHold$7.00High
i
Rating by Brandon Henry at Royal Bank of Canada
4/1/2019Stifel NicolausSet Price TargetHold$7.00Low
i
Rating by Mathew Blackman at Stifel Nicolaus
2/26/2019BTIG ResearchReiterated RatingBuyLow
i
11/4/2018BTIG ResearchReiterated RatingBuyMedium
i
11/2/2018OppenheimerSet Price TargetHold$30.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
10/3/2018OppenheimerReiterated RatingHoldHigh
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
10/3/2018Piper Jaffray CompaniesLower Price TargetNeutral$30.00High
i
8/23/2018BTIG ResearchLower Price TargetBuy$40.00Medium
i
8/11/2018Stifel NicolausSet Price TargetHold$30.00High
i
Rating by Mathew Blackman at Stifel Nicolaus
8/10/2018BMO Capital MarketsReiterated RatingMarket Perform ➝ Hold$65.00 ➝ $40.00High
i
8/10/2018OppenheimerSet Price TargetHold$40.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/10/2018Piper Jaffray CompaniesDowngradeOverweight ➝ NeutralHigh
i
5/21/2018Stifel NicolausBoost Price TargetHold ➝ Hold$45.00 ➝ $50.00High
i
5/3/2018OppenheimerSet Price TargetHold$50.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
2/22/2018OppenheimerSet Price TargetHold$50.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
1/2/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
i
12/12/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ OverweightHigh
i
11/8/2017Canaccord GenuityReiterated RatingHold$50.00N/A
i
11/8/2017Stifel NicolausLower Price TargetHold$60.00 ➝ $55.00N/A
i
Rating by Mathew Blackman at Stifel Nicolaus
11/8/2017Royal Bank of CanadaLower Price TargetSector Perform$50.00 ➝ $40.00N/A
i
10/9/2017Canaccord GenuityReiterated RatingHold$50.00N/A
i
10/6/2017Stifel NicolausSet Price TargetHold$60.00N/A
i
Rating by Mathew Blackman at Stifel Nicolaus
10/3/2017Royal Bank of CanadaReiterated RatingHold$50.00High
i
9/27/2017Canaccord GenuityReiterated RatingHold$50.00Medium
i
8/4/2017Canaccord GenuityReiterated RatingHoldMedium
i
8/3/2017OppenheimerSet Price TargetHold$50.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/2/2017Stifel NicolausSet Price TargetHold$60.00High
i
Rating by Mathew Blackman at Stifel Nicolaus
7/31/2017Royal Bank of CanadaReiterated RatingHold$50.00Medium
i
6/5/2017Stifel NicolausReiterated RatingBuy$50.00 ➝ $55.00Medium
i
5/18/2017OppenheimerDowngradeOutperform ➝ Market Perform$60.00Medium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
5/18/2017Royal Bank of CanadaReiterated RatingHoldMedium
i
5/18/2017BMO Capital MarketsReiterated RatingHold$50.00High
i
5/18/2017Canaccord GenuityReiterated RatingHold$50.00High
i
Rating by Jason Mills at Canaccord Genuity
5/18/2017StephensDowngradeOverweight ➝ Equal Weight$60.00High
i
5/18/2017BTIG ResearchDowngradeBuy ➝ Neutral$70.00High
i
5/18/2017Stifel NicolausDowngradeBuy ➝ Hold$100.00 ➝ $55.00High
i
4/13/2017Royal Bank of CanadaReiterated RatingHold$80.00Low
i
4/11/2017BMO Capital MarketsReiterated RatingHold$70.00Low
i
4/5/2017OppenheimerReiterated RatingBuyHigh
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
3/22/2017OppenheimerReiterated RatingBuyLow
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
2/23/2017OppenheimerSet Price TargetBuy$100.00N/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
1/12/2017BMO Capital MarketsDowngradeOutperform ➝ Market Perform$140.00 ➝ $95.00N/A
i
1/6/2017BTIG ResearchReiterated RatingBuy$110.00 ➝ $90.00N/A
i
1/6/2017Royal Bank of CanadaReiterated RatingHold$80.00N/A
i
12/28/2016Canaccord GenuityReiterated RatingHold$75.00 ➝ $63.00N/A
i
Rating by Jason Mills at Canaccord Genuity
12/13/2016Canaccord GenuityReiterated RatingHoldN/A
i
Rating by Jason Mills at Canaccord Genuity
12/13/2016OppenheimerSet Price TargetBuy$110.00N/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
12/7/2016SVB LeerinkReiterated RatingMarket Perform$110.00 ➝ $80.00N/A
i
Rating by Ravi Misra at SVB Leerink LLC
12/4/2016Canaccord GenuityDowngradeBuy ➝ Hold$135.00 ➝ $75.00N/A
i
Rating by Jason Mills at Canaccord Genuity
12/4/2016JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$140.00 ➝ $100.00N/A
i
11/21/2016OppenheimerSet Price TargetBuy$110.00N/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
11/19/2016SVB LeerinkSet Price TargetHold$80.00N/A
i
Rating by Ravi Misra at SVB Leerink LLC
11/16/2016BMO Capital MarketsDowngradeOutperform ➝ Market Perform$140.00 ➝ $95.00N/A
i
11/16/2016GuggenheimDowngradeBuy ➝ NeutralN/A
i
11/16/2016Canaccord GenuityDowngradeBuy ➝ Hold$135.00 ➝ $75.00N/A
i
Rating by Jason Mills at Canaccord Genuity
11/16/2016JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$140.00 ➝ $100.00N/A
i
11/2/2016OppenheimerSet Price TargetBuy$150.00N/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
11/2/2016SVB LeerinkSet Price TargetHold$130.00 ➝ $110.00N/A
i
Rating by ravi misra at SVB Leerink LLC
10/30/2016Canaccord GenuitySet Price TargetBuy$150.00N/A
i
Rating by Jason Mills at Canaccord Genuity
9/27/2016OppenheimerReiterated RatingOutperform$150.00N/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
9/17/2016SVB LeerinkSet Price TargetHold$130.00N/A
i
Rating by ravi misra at SVB Leerink LLC
9/6/2016SVB LeerinkInitiated CoverageMarket Perform$130.00N/A
i
Rating by R. Misra at SVB Leerink LLC
8/3/2016BMO Capital MarketsReiterated RatingBuy$150.00N/A
i
8/3/2016BTIG ResearchReiterated RatingBuy$160.00N/A
i
Rating by Sean Lavin at BTIG Research
8/3/2016Piper Jaffray CompaniesReiterated RatingOverweight$150.00N/A
i
8/3/2016OppenheimerSet Price TargetBuy$160.00 ➝ $150.00N/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/3/2016Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$170.00 ➝ $120.00N/A
i
7/12/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by Jason Mills at Canaccord Genuity
7/7/2016BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$115.00 ➝ $160.00N/A
i
7/6/2016OppenheimerReiterated RatingOutperform$150.00 ➝ $160.00N/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
(Data available from 6/16/2016 forward)
Endologix logo
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.03
$0.02
$0.22

52 Week Range

Now: N/A

Volume

N/A

Average Volume

1,278,341 shs

Market Capitalization

$382,000.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73

Frequently Asked Questions

What sell-side analysts currently cover shares of Endologix?

The following Wall Street analysts have issued stock ratings on Endologix in the last year: Zacks Investment Research.
View the latest analyst ratings for ELGX.

What is the current price target for Endologix?

0 Wall Street analysts have set twelve-month price targets for Endologix in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Endologix in the next year.
View the latest price targets for ELGX.

What is the current consensus analyst rating for Endologix?

Endologix currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ELGX.

What other companies compete with Endologix?

How do I contact Endologix's investor relations team?

Endologix's physical mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier's listed phone number is 949-595-7200 and its investor relations email address is [email protected] The official website for Endologix is www.endologix.com.